Evidence map›Paper›PMID 23511562›Full record

Trial reportBritish journal of cancer2013

Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.

G Pfeiler, H Stöger, P Dubsky, B Mlineritsch, C Singer, M Balic, F Fitzal, M Moik, W Kwasny, U Selim and 12 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00309491 (A Randomized Phase III Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal, Hormone Receptor-positive Patients), which is not on this map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00309491 phase3completednot on this map

A Randomized Phase III Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal, Hormone Receptor-positive Patients

TypeinterventionalSponsorAustrian Breast & Colorectal Cancer Study GroupRan1990 to 2000Enrolled2,021ConditionsEarly-stage Breast CancerArmsTamoxifen alone, Tamoxifen + Aminoglutethimide
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies.Annals of oncology : official journal of the European Society for Medical Oncology · 2014
    Pooled it
  4. Trial
  5. Review
  6. Review
  7. Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022
    Review
  8. Review
  9. Article
  10. Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Article
  11. Review
  12. Review
  13. Obesity and breast cancer: not only a risk factor of the disease.Current treatment options in oncology · 2015
    Review
  14. Review
  15. Article
  16. The obesity-inflammation-eicosanoid axis in breast cancer.Journal of mammary gland biology and neoplasia · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 1 country.

G PfeilerDivision of Gynecology and Gynecological Oncology, Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
H Stöger
P Dubsky
B Mlineritsch
C Singer
M Balic
F Fitzal
M Moik
W Kwasny
U Selim
K Renner
F Ploner
G G Steger
M Seifert
F Hofbauer
P Sandbichler
H Samonigg
R Jakesz
R Greil
C Fesl
M Gnant
ABCSG
Medical University of Graz · ATParacelsus Medical University · ATComprehensive Cancer Center Vienna · ATAustrian Breast & Colorectal Cancer Study Group · ATFachhochschule Wiener Neustadt · ATHanusch Hospital · ATKrankenhaus Oberndorf · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere exists evidence that body mass index (BMI) impacts on the efficacy of aromatase inhibitors in patients with breast cancer. The relationship between BMI and the efficacy of tamoxifen is conflicting. We investigated the impact of BMI on the efficacy of single tamoxifen and tamoxifen plus an aromatase inhibitor in the well-defined prospective study population of the ABCSG-06 trial.

methodsABCSG-06 investigated the efficacy of tamoxifen vs tamoxifen plus aminoglutethimide in postmenopausal women with hormone receptor-positive breast cancer. Taking BMI at baseline, patients were classified as normal weight (BMI=18.5-24.9 kg m(-)(2)), overweight (BMI=25-29.9 kg m(-)(2)), and obese (30 kg m(-)(2)) according to WHO criteria.

resultsOverweight+obese patients had an increased risk for distant recurrences (hazard ratio (HR): 1.51; Cox P=0·018) and a worse overall survival (OS; HR: 1·49; Cox P=0·052) compared with normal weight patients. Analysing patients treated with single tamoxifen only, no difference between overweight+obese patients and normal weight patients regarding distant recurrence-free survival (HR: 1.35; Cox P=0·24) and OS (HR: 0.99; Cox P=0·97) could be observed. In contrast, in the group of patients treated with the combination of tamoxifen plus aminoglutethimide, overweight+obese patients had an increased risk for distant recurrences (1.67; Cox P=0·03) and a worse OS (1.47; Cox P=0·11) compared with normal weight patients.

conclusionBMI impacts on the efficacy of aromatase inhibitor-based treatment but not single tamoxifen.

Indexed as

AgedAged, 80 and overAminoglutethimideAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBody Mass IndexBreast NeoplasmsFemaleHumansMiddle AgedOverweightPostmenopauseProspective StudiesReceptors, Cell SurfaceTamoxifenAminoglutethimideAntineoplastic Agents, HormonalAromatase InhibitorsReceptors, Cell SurfaceTamoxifen

Identifiers

PMID23511562
PMCPMC3629426
OpenAlexW2089501709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.